Company: TELO
Filing Date: 2025-02-14
Form Type: S-3
Source: 0001493152-25-006943
Chunk: 47

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-14
Form: S-3
Chunk 47
---
 securities activities may involve securities and/or instruments of ours or our affiliates. Rodman & Renshaw or its affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. Except as disclosed in this prospectus, we have no present arrangements with Rodman & Renshaw for any further services.

This summary of the material provisions of the sales agreement does not purport to be a complete statement of its terms and conditions. A copy of the sales agreement is filed as an exhibit to the registration statement of which this prospectus forms a part.

This prospectus and accompanying base prospectus in electronic format may be made available on a website maintained by Rodman & Renshaw and Rodman & Renshaw may distribute this prospectus electronically.

American Stock Transfer (also known as Equiniti) is the transfer agent and registrar for our common stock. The transfer agent’s address is 6201 15th Avenue, Brooklyn, NY 11219.

<div align='center'>LEGAL MATTERS</div>

The validity of the securities offered by this prospectus will be passed upon by Pearl Cohen Zedek Latzer Baratz LLP, New York, New York. Haynes and Boone, LLP, New York, New York, is acting as counsel for Rodman & Renshaw in connection with this offering.

<div align='center'>EXPERTS</div>

The financial statements of Telomir Pharmaceuticals, Inc. as of December 31, 2024 and for the year then ended included in the Annual Report on Form 10-K for the year ended December 31, 2024, have been incorporated by reference herein and in this prospectus in reliance upon the report of Salberg & Company P.A. (which report includes an explanatory paragraph regarding the existence of substantial doubt about the Company’s ability to continue as a going concern), independent registered public accounting firm, incorporated by reference herein, and given upon the authority of said firm as experts in accounting and auditing.

The financial statements of Telomir Pharmaceuticals, Inc. as of December 31, 2023 and for the year then ended included in the Annual Report on Form 10-K for the year ended December 31, 2024, have been incorporated by reference herein and in this prospectus in reliance upon the report of Cherry Bekaert LLP (which report includes an explanatory